ConductScience.org, home
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
API referenceFor AI assistants

Trial · NCT02207621

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

141 to 160 of 168

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousCellulitisInfections and infestationsAR-13324 Ophthalmic Solution 0.02% BID0253
seriousPeritonitis BacterialInfections and infestationsAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousPeritonitis BacterialInfections and infestationsTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousPeritonitis BacterialInfections and infestationsAR-13324 Ophthalmic Solution 0.02% BID0253
seriousPneumoniaInfections and infestationsAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousPneumoniaInfections and infestationsTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousPneumoniaInfections and infestationsAR-13324 Ophthalmic Solution 0.02% BID0253
seriousUrinary Tract InfectionInfections and infestationsAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousUrinary Tract InfectionInfections and infestationsTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousUrinary Tract InfectionInfections and infestationsAR-13324 Ophthalmic Solution 0.02% BID0253
seriousFluid OverloadMetabolism and nutrition disordersAR-13324 Ophthalmic Solution 0.02% & Placebo1251
seriousFluid OverloadMetabolism and nutrition disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousFluid OverloadMetabolism and nutrition disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousAcute Kidney InjuryRenal and urinary disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousAcute Kidney InjuryRenal and urinary disordersTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousAcute Kidney InjuryRenal and urinary disordersAR-13324 Ophthalmic Solution 0.02% BID1253
seriousRenal FailureRenal and urinary disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousRenal FailureRenal and urinary disordersTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousRenal FailureRenal and urinary disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousAngioedemaSkin and subcutaneous tissue disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02207621/events?page=8

API referenceFor AI assistants